FENC
Income statement / Annual
Last year (2023), Fennec Pharmaceuticals Inc.'s total revenue was $21.25 M,
an increase of 1,284.50% from the previous year.
In 2023, Fennec Pharmaceuticals Inc.'s net income was -$16.05 M.
See Fennec Pharmaceuticals Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$21.25 M
|
$1.54 M
|
$0.00
|
$170,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.26 M |
$86,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$19.99 M |
$1.45 M |
$0.00 |
$170,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.94 |
0.94 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$56,000.00
|
$3.53 M
|
$4.98 M
|
$5.11 M
|
$5.61 M
|
$5.01 M
|
$1.94 M
|
$472,000.00
|
$256,000.00
|
$357,000.00
|
| General & Administrative
Expenses |
$20.59 M
|
$17.72 M
|
$12.24 M
|
$12.95 M
|
$7.40 M
|
$5.40 M
|
$5.02 M
|
$2.40 M
|
$1.63 M
|
$2.52 M
|
| Selling & Marketing
Expenses |
$12.12 M
|
$2.79 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$32.71 M
|
$20.51 M
|
$12.24 M
|
$12.95 M
|
$7.40 M
|
$5.40 M
|
$5.02 M
|
$2.40 M
|
$1.63 M
|
$2.52 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$9,000.00 |
-$17,000.00 |
$6,000.00 |
-$8,000.00 |
-$14,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$32.76 M |
$24.04 M |
$17.22 M |
$18.06 M |
$13.01 M |
$10.41 M |
$6.95 M |
$2.87 M |
$1.89 M |
$2.88 M |
| Cost And Expenses |
$34.02 M |
$24.12 M |
$17.22 M |
$18.06 M |
$13.01 M |
$10.41 M |
$6.95 M |
$2.87 M |
$1.89 M |
$2.88 M |
| Interest Income |
$441,000.00 |
$195,000.00 |
$54,000.00 |
$87,000.00 |
$322,323.00 |
$0.00 |
$0.00 |
$0.00 |
$3,000.00 |
$2,000.00 |
| Interest Expense |
$3.39 M |
$978,000.00 |
$126,000.00 |
$9,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2,000.00 |
| Depreciation &
Amortization |
$287,000.00
|
$149,000.00
|
$17.22 M
|
$402,000.00
|
$13.01 M
|
$10.41 M
|
$6.95 M
|
$2.87 M
|
-$1.23 M
|
-$699,000.00
|
| EBITDA |
-$12.36 M
|
-$22.59 M
|
-$123,000.00
|
-$17.89 M
|
$234,000.00
|
$521,000.00
|
-$95,000.00
|
$82,000.00
|
-$1.89 M
|
-$2.88 M
|
| EBITDA Ratio |
-0.58 |
-14.69 |
0 |
-105.79 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.6
|
-14.72
|
0
|
-105.21
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$3.27 M
|
-$1.13 M
|
-$123,000.00
|
-$224,000.00
|
$234,000.00
|
$521,000.00
|
-$95,000.00
|
$82,000.00
|
$1.28 M
|
$701,000.00
|
| Income Before Tax |
-$16.05 M |
-$23.71 M |
-$17.35 M |
-$18.11 M |
-$12.78 M |
-$9.89 M |
-$7.05 M |
-$2.79 M |
-$659,000.00 |
-$2.18 M |
| Income Before Tax Ratio
|
-0.75
|
-15.45
|
0
|
-106.52
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$1.13 M |
$110,000.00 |
-$187,000.00 |
-$315,000.00 |
-$348,000.00 |
-$47,000.00 |
-$8,000.00 |
-$3,000.00 |
-$2,000.00 |
| Net Income |
-$16.05 M |
-$24.84 M |
-$17.46 M |
-$17.92 M |
-$12.46 M |
-$9.89 M |
-$7.05 M |
-$2.79 M |
-$659,000.00 |
-$2.18 M |
| Net Income Ratio |
-0.75 |
-16.18 |
0 |
-105.42 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.6 |
-0.95 |
-0.67 |
-0.76 |
-0.63 |
-0.52 |
-0.47 |
-0.22 |
-0.0609 |
-0.22 |
| EPS Diluted |
-0.6 |
-0.95 |
-0.67 |
-0.76 |
-0.63 |
-0.52 |
-0.47 |
-0.22 |
-0.0609 |
-0.22 |
| Weighted Average Shares
Out |
$26.57 M
|
$26.28 M
|
$26.01 M
|
$23.70 M
|
$19.90 M
|
$18.94 M
|
$14.99 M
|
$12.68 M
|
$10.83 M
|
$9.87 M
|
| Weighted Average Shares
Out Diluted |
$26.57 M
|
$26.28 M
|
$26.01 M
|
$23.70 M
|
$19.90 M
|
$19.02 M
|
$15.01 M
|
$12.77 M
|
$10.83 M
|
$9.87 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
